Compare Recursion Pharmaceuticals Inc (RXRX) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs BlackRock TCP Capital Corp — how do they compare? Recursion Pharmaceuticals Inc trades at $3.99 (market cap $2.14B), while BlackRock TCP Capital Corp trades at $4.04 (market cap $337.71M). The key difference: Recursion Pharmaceuticals Inc is far larger — about 6.3× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays a 18.88% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and BlackRock TCP Capital Corp for 88 Days on average.
| RXRX | TCPC | |
|---|---|---|
Market Cap | $2.14B | $337.71M |
Volume | 30,789,535 | 436,109 |
Sector | Health | Financials |
52-Week High | $6.79 | $6.20 |
52-Week Low | $2.84 | $3.13 |
Typical Hold Time | 22 Days | 88 Days |
Enterprise Value | $1.66B | $1.09B |
Dividend Yield | — | 18.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
TCPC trades at $3.94, down 1.25% today, with a bearish technical signal and mixed fundamentals. The company reported negative revenue and net income for 2025, though recent earnings beat expectations. A strategic portfolio sale of $523 million aims to reduce leverage, while analyst sentiment leans cautious with 69% hold ratings. The stock shows a low P/B ratio of 0.61, suggesting potential undervaluation relative to assets.
Outlook remains challenged by persistent negative profitability and revenue trends, with projected declines through 2026. The strategic review and dividend yield near 4.3% offer some upside, but risks include class action lawsuits and execution uncertainty. Investors should weigh the discount to book value against fundamental headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
